News | April 08, 2025
Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
No safety signals related to the vaccine candidate were identified
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Subscribe To Our Newsletter & Stay Updated
